Biohaven Pharmaceutical Stock Price, News & Analysis (NYSE:BHVN)

$29.58 -0.03 (-0.10 %)
(As of 02/21/2018 08:25 AM ET)
Previous Close$29.61
Today's Range$29.16 - $30.15
52-Week Range$17.00 - $39.51
Volume249,500 shs
Average Volume413,376 shs
Market Capitalization$1.07 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Biohaven Pharmaceutical (NYSE:BHVN)

Biohaven Pharmaceutical logoBiohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.

Receive BHVN News and Ratings via Email

Sign-up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNYSE:BHVN
CUSIPN/A
Phone203-404-0410

Debt

Debt-to-Equity RatioN/A
Current Ratio8.12%
Quick Ratio8.12%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees12
Outstanding Shares36,020,000

Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions

What is Biohaven Pharmaceutical's stock symbol?

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Where is Biohaven Pharmaceutical's stock going? Where will Biohaven Pharmaceutical's stock price be in 2018?

6 equities research analysts have issued twelve-month target prices for Biohaven Pharmaceutical's shares. Their forecasts range from $30.00 to $48.00. On average, they expect Biohaven Pharmaceutical's stock price to reach $38.00 in the next year. View Analyst Ratings for Biohaven Pharmaceutical.

What are Wall Street analysts saying about Biohaven Pharmaceutical stock?

Here are some recent quotes from research analysts about Biohaven Pharmaceutical stock:

  • 1. According to Zacks Investment Research, "Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. " (2/14/2018)
  • 2. Needham & Company LLC analysts commented, "Biohaven reported 3Q17 financial results and we spoke w/ mgmt for an update. Rimegepant Phase 3 trials in Acute Migraine are nearing completion of enrollment and mgmt reiterated guidance for top-line results in 1Q18. We expect a positive outcome based on strength of Phase 2b data. Biohaven recently initiated a registration bioequivalence trial of BHV-0223 in Amyotrophic Lateral Sclerosis (ALS) and we believe results will be available in early 2018. We expect company to submit 505(b)(2) application (oral riluzole disintegrating tablet) by mid-2017. BHV5000 IND submission is on track, but BH3500 has been pushed into 2018 because of technical regulatory matters tied to manufacturing. Reiterate BUY, w/ expectations for upside around rimegepant Phase 3 outcome." (11/15/2017)

Who are some of Biohaven Pharmaceutical's key competitors?

Who are Biohaven Pharmaceutical's key executives?

Biohaven Pharmaceutical's management team includes the folowing people:

  • Declan Doogan M.D., Independent Chairman of the Board (Age 65)
  • Vlad Coric M.D., Chief Executive Officer, Director (Age 46)
  • James Engelhart, Chief Financial Officer (Age 53)
  • Charles Conway Ph.D., Chief Scientific Officer (Age 55)
  • Kimberly Gentile, Vice President - Clinical Operations (Age 51)
  • Robert Berman M.D., Chief Medical Officer (Age 54)
  • John Tilton, Chief Commercial Officer (Age 49)
  • Gregory H. Bailey M.D., Director (Age 62)
  • John W. Childs, Director (Age 75)
  • Julia P. Gregory, Director (Age 64)

When did Biohaven Pharmaceutical IPO?

(BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Who owns Biohaven Pharmaceutical stock?

Biohaven Pharmaceutical's stock is owned by a number of of institutional and retail investors. Top institutional investors include BAILEY GREGORY (8.20%), DOOGAN DECLAN (6.20%), VHCP Management II LLC (4.77%), Alliancebernstein L.P. (4.44%), BlackRock Inc. (3.20%) and Eagle Asset Management Inc. (3.07%). Company insiders that own Biohaven Pharmaceutical stock include Albert Cha, Declan Doogan, Gregory Bailey, James Engelhart, John Tilton, Kimberly Gentile, Portage Biotech Inc, Robert Berman and Vlad Coric. View Institutional Ownership Trends for Biohaven Pharmaceutical.

Who sold Biohaven Pharmaceutical stock? Who is selling Biohaven Pharmaceutical stock?

Biohaven Pharmaceutical's stock was sold by a variety of institutional investors in the last quarter, including TIAA CREF Investment Management LLC, Perceptive Advisors LLC, Bank of New York Mellon Corp, Teachers Advisors LLC, Wells Fargo & Company MN and Rhumbline Advisers. Company insiders that have sold Biohaven Pharmaceutical company stock in the last year include Declan Doogan, Gregory Bailey, James Engelhart, John Tilton, Kimberly Gentile, Portage Biotech Inc, Robert Berman and Vlad Coric. View Insider Buying and Selling for Biohaven Pharmaceutical.

Who bought Biohaven Pharmaceutical stock? Who is buying Biohaven Pharmaceutical stock?

Biohaven Pharmaceutical's stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Carillon Tower Advisers Inc., Millennium Management LLC, Eagle Asset Management Inc., AXA, Emerald Advisers Inc. PA, Candriam Luxembourg S.C.A. and VHCP Management II LLC. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Albert Cha, James Engelhart and Robert Berman. View Insider Buying and Selling for Biohaven Pharmaceutical.

How do I buy Biohaven Pharmaceutical stock?

Shares of Biohaven Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biohaven Pharmaceutical's stock price today?

One share of Biohaven Pharmaceutical stock can currently be purchased for approximately $29.58.

How big of a company is Biohaven Pharmaceutical?

Biohaven Pharmaceutical has a market capitalization of $1.07 billion. Biohaven Pharmaceutical employs 12 workers across the globe.

How can I contact Biohaven Pharmaceutical?

Biohaven Pharmaceutical's mailing address is 234 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.


MarketBeat Community Rating for Biohaven Pharmaceutical (BHVN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  86 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  193
MarketBeat's community ratings are surveys of what our community members think about Biohaven Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Biohaven Pharmaceutical (NYSE:BHVN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $38.00$38.00$40.80$31.75
Price Target Upside: 73.28% upside73.28% upside70.43% upside31.80% upside

Biohaven Pharmaceutical (NYSE:BHVN) Consensus Price Target History

Price Target History for Biohaven Pharmaceutical (NYSE:BHVN)

Biohaven Pharmaceutical (NYSE:BHVN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/15/2017Canaccord GenuityInitiated CoverageBuy -> Buy$30.00MediumView Rating Details
12/11/2017Piper Jaffray CompaniesSet Price TargetBuy$48.00MediumView Rating Details
11/15/2017Needham & Company LLCReiterated RatingBuy$36.00N/AView Rating Details
10/3/2017William BlairReiterated RatingOutperformLowView Rating Details
10/3/2017Morgan StanleyReiterated RatingOverweight -> Overweight$47.00 -> $38.00HighView Rating Details
5/30/2017BarclaysInitiated CoverageOverweight -> Overweight$30.00HighView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Biohaven Pharmaceutical (NYSE:BHVN) Earnings History and Estimates Chart

Earnings by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Biohaven Pharmaceutical (NYSE BHVN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q3 2017($1.22)($1.19)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.57)($1.78)ViewN/AView Earnings Details
6/16/2017Q1 2017($0.88)($1.74)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Biohaven Pharmaceutical (NYSE:BHVN) Earnings Estimates

Current Year EPS Consensus Estimate: $-6.4 EPS
Next Year EPS Consensus Estimate: $-4.64 EPS

Dividends

Dividend History for Biohaven Pharmaceutical (NYSE:BHVN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Biohaven Pharmaceutical (NYSE BHVN) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 52.82%
Insider Trades by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)
Insider Trades by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Biohaven Pharmaceutical (NYSE BHVN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/12/2018Robert BermanInsiderSell35,000$30.42$1,064,700.00View SEC Filing  
2/1/2018Kimberly GentileVPSell5,000$32.78$163,900.005,000View SEC Filing  
1/31/2018Gregory BaileyDirectorSell50,000$33.71$1,685,500.002,516,701View SEC Filing  
1/22/2018Gregory BaileyDirectorSell49,000$30.76$1,507,240.002,583,289View SEC Filing  
1/22/2018James EngelhartCFOSell10,000$32.50$325,000.0013,576View SEC Filing  
1/19/2018Portage Biotech Inc.Major ShareholderSell35,119$30.03$1,054,623.57View SEC Filing  
1/18/2018Declan DooganDirectorSell128,058$26.95$3,451,163.102,583,289View SEC Filing  
1/16/2018Gregory BaileyDirectorSell40,000$26.52$1,060,800.00View SEC Filing  
1/12/2018Declan DooganDirectorSell121,942$26.78$3,265,606.76View SEC Filing  
1/10/2018Declan DooganDirectorSell40,362$27.69$1,117,623.78View SEC Filing  
1/10/2018Robert BermanInsiderSell35,000$27.52$963,200.00View SEC Filing  
1/9/2018Portage Biotech Inc.Major ShareholderSell84,881$30.06$2,551,522.866,278,504View SEC Filing  
1/5/2018Portage Biotech Inc.Major ShareholderSell22,996$30.03$690,569.886,278,504View SEC Filing  
1/4/2018Gregory BaileyDirectorSell50,000$28.71$1,435,500.001,187,275View SEC Filing  
1/3/2018Portage Biotech Inc.Major ShareholderSell35,650$28.61$1,019,946.50124,371View SEC Filing  
1/2/2018Kimberly GentileVPSell5,000$27.60$138,000.005,000View SEC Filing  
12/20/2017Gregory BaileyDirectorSell39,430$26.31$1,037,403.301,234,077View SEC Filing  
12/19/2017Robert BermanInsiderSell10,000$24.10$241,000.00View SEC Filing  
12/11/2017Robert BermanInsiderSell25,000$21.28$532,000.00View SEC Filing  
12/1/2017Kimberly GentileVPSell5,000$21.99$109,950.00View SEC Filing  
11/30/2017Gregory BaileyDirectorSell9,970$25.48$254,035.601,262,759View SEC Filing  
11/27/2017Gregory BaileyDirectorSell20,600$25.92$533,952.001,289,699View SEC Filing  
11/24/2017Gregory BaileyDirectorSell600$26.02$15,612.001,289,699View SEC Filing  
11/14/2017Robert BermanInsiderSell160,000$25.76$4,121,600.00View SEC Filing  
11/10/2017James EngelhartCFOSell30,538$26.58$811,700.0425,176View SEC Filing  
11/9/2017Robert BermanInsiderSell27,423$26.60$729,451.80View SEC Filing  
11/1/2017John TiltonInsiderSell30,000$29.25$877,500.0030,000View SEC Filing  
11/1/2017Kimberly GentileVPSell5,000$29.28$146,400.005,000View SEC Filing  
11/1/2017Vlad CoricCEOSell150,000$29.41$4,411,500.00View SEC Filing  
5/9/2017Albert ChaDirectorBuy470,000$17.00$7,990,000.00View SEC Filing  
5/9/2017James EngelhartCFOBuy2,500$17.00$42,500.003,576View SEC Filing  
5/9/2017Robert BermanInsiderBuy50$17.00$850.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Biohaven Pharmaceutical (NYSE BHVN) News Headlines

Source:
DateHeadline
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Sells $1,064,700.00 in StockBiohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Sells $1,064,700.00 in Stock
www.americanbankingnews.com - February 14 at 9:28 PM
Biohaven Pharmaceutical (BHVN) Upgraded at Zacks Investment ResearchBiohaven Pharmaceutical (BHVN) Upgraded at Zacks Investment Research
www.americanbankingnews.com - February 14 at 7:12 PM
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Receives Consensus Recommendation of "Buy" from BrokeragesBiohaven Pharmaceutical Holding Co Ltd (BHVN) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - February 7 at 3:24 AM
-$1.33 Earnings Per Share Expected for Biohaven Pharmaceutical Holding Co Ltd (BHVN) This Quarter-$1.33 Earnings Per Share Expected for Biohaven Pharmaceutical Holding Co Ltd (BHVN) This Quarter
www.americanbankingnews.com - February 6 at 12:43 PM
Insider Selling: Biohaven Pharmaceutical Holding Co Ltd (BHVN) VP Sells 5,000 Shares of StockInsider Selling: Biohaven Pharmaceutical Holding Co Ltd (BHVN) VP Sells 5,000 Shares of Stock
www.americanbankingnews.com - February 2 at 9:44 PM
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Director Sells $1,685,500.00 in StockBiohaven Pharmaceutical Holding Co Ltd (BHVN) Director Sells $1,685,500.00 in Stock
www.americanbankingnews.com - February 2 at 9:14 PM
Stock Traders Buy Large Volume of Biohaven Pharmaceutical Call Options (BHVN)Stock Traders Buy Large Volume of Biohaven Pharmaceutical Call Options (BHVN)
www.americanbankingnews.com - February 2 at 1:16 AM
Biohaven Pharmaceutical (BHVN) Rating Lowered to Sell at Zacks Investment ResearchBiohaven Pharmaceutical (BHVN) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 30 at 6:56 PM
Biohaven Pharmaceutical Holding Co Ltd (BHVN) CFO Sells $325,000.00 in StockBiohaven Pharmaceutical Holding Co Ltd (BHVN) CFO Sells $325,000.00 in Stock
www.americanbankingnews.com - January 24 at 9:10 PM
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Sells $8,049,345,920.00 in StockBiohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Sells $8,049,345,920.00 in Stock
www.americanbankingnews.com - January 24 at 9:08 PM
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Major Shareholder Sells $1,054,623.57 in StockBiohaven Pharmaceutical Holding Co Ltd (BHVN) Major Shareholder Sells $1,054,623.57 in Stock
www.americanbankingnews.com - January 24 at 9:08 PM
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Director Gregory Bailey Sells 49,000 SharesBiohaven Pharmaceutical Holding Co Ltd (BHVN) Director Gregory Bailey Sells 49,000 Shares
www.americanbankingnews.com - January 23 at 9:32 PM
Head to Head Survey: Biohaven Pharmaceutical (BHVN) vs. Novelion Therapeutics (NVLN)Head to Head Survey: Biohaven Pharmaceutical (BHVN) vs. Novelion Therapeutics (NVLN)
www.americanbankingnews.com - January 20 at 11:30 PM
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Director Declan Doogan Sells 128,058 SharesBiohaven Pharmaceutical Holding Co Ltd (BHVN) Director Declan Doogan Sells 128,058 Shares
www.americanbankingnews.com - January 18 at 9:30 PM
Insider Selling: Biohaven Pharmaceutical Holding Co Ltd (BHVN) Director Sells 40,000 Shares of StockInsider Selling: Biohaven Pharmaceutical Holding Co Ltd (BHVN) Director Sells 40,000 Shares of Stock
www.americanbankingnews.com - January 18 at 9:28 PM
BRIEF-Biohaven says U.S. FDA has notified co it may proceed with clinical investigation of BHV-5000BRIEF-Biohaven says U.S. FDA has notified co it may proceed with clinical investigation of BHV-5000
www.reuters.com - January 18 at 5:23 PM
Biohaven (BHVN) Granted FDA Clearance to Commencement Clinical Development For BHV-5000Biohaven (BHVN) Granted FDA Clearance to Commencement Clinical Development For BHV-5000
www.streetinsider.com - January 18 at 5:23 PM
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Sees Large Increase in Short InterestBiohaven Pharmaceutical Holding Co Ltd (BHVN) Sees Large Increase in Short Interest
www.americanbankingnews.com - January 17 at 1:14 AM
Critical Analysis: Biohaven Pharmaceutical (BHVN) and The CompetitionCritical Analysis: Biohaven Pharmaceutical (BHVN) and The Competition
www.americanbankingnews.com - January 15 at 7:14 PM
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Given Consensus Recommendation of "Buy" by BrokeragesBiohaven Pharmaceutical Holding Co Ltd (BHVN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 13 at 4:01 AM
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Robert Berman Sells 35,000 SharesBiohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Robert Berman Sells 35,000 Shares
www.americanbankingnews.com - January 12 at 9:28 PM
Insider Selling: Biohaven Pharmaceutical Holding Co Ltd (BHVN) Director Sells 121,942 Shares of StockInsider Selling: Biohaven Pharmaceutical Holding Co Ltd (BHVN) Director Sells 121,942 Shares of Stock
www.americanbankingnews.com - January 12 at 9:28 PM
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Director Sells $1,117,623.78 in StockBiohaven Pharmaceutical Holding Co Ltd (BHVN) Director Sells $1,117,623.78 in Stock
www.americanbankingnews.com - January 12 at 9:26 PM
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Major Shareholder Portage Biotech Inc. Sells 22,996 SharesBiohaven Pharmaceutical Holding Co Ltd (BHVN) Major Shareholder Portage Biotech Inc. Sells 22,996 Shares
www.americanbankingnews.com - January 9 at 9:38 PM
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Major Shareholder Sells $2,551,522.86 in StockBiohaven Pharmaceutical Holding Co Ltd (BHVN) Major Shareholder Sells $2,551,522.86 in Stock
www.americanbankingnews.com - January 9 at 9:38 PM
Biohaven Pharmaceutical (BHVN) versus Its Rivals Financial ReviewBiohaven Pharmaceutical (BHVN) versus Its Rivals Financial Review
www.americanbankingnews.com - January 7 at 3:11 AM
Contrasting Biohaven Pharmaceutical (BHVN) & The CompetitionContrasting Biohaven Pharmaceutical (BHVN) & The Competition
www.americanbankingnews.com - January 6 at 5:12 PM
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Director Gregory Bailey Sells 50,000 SharesBiohaven Pharmaceutical Holding Co Ltd (BHVN) Director Gregory Bailey Sells 50,000 Shares
www.americanbankingnews.com - January 5 at 9:10 PM
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Major Shareholder Portage Biotech Inc. Sells 35,650 SharesBiohaven Pharmaceutical Holding Co Ltd (BHVN) Major Shareholder Portage Biotech Inc. Sells 35,650 Shares
www.americanbankingnews.com - January 4 at 7:30 PM
Biohaven Pharmaceutical (BHVN) versus Its Peers Head-To-Head ReviewBiohaven Pharmaceutical (BHVN) versus Its Peers Head-To-Head Review
www.americanbankingnews.com - January 3 at 5:34 AM
Critical Comparison: Biohaven Pharmaceutical (BHVN) & Its RivalsCritical Comparison: Biohaven Pharmaceutical (BHVN) & Its Rivals
www.americanbankingnews.com - December 29 at 3:28 AM
Reviewing Biohaven Pharmaceutical (BHVN) and Its RivalsReviewing Biohaven Pharmaceutical (BHVN) and Its Rivals
www.americanbankingnews.com - December 28 at 8:48 AM
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Director Gregory Bailey Sells 39,430 SharesBiohaven Pharmaceutical Holding Co Ltd (BHVN) Director Gregory Bailey Sells 39,430 Shares
www.americanbankingnews.com - December 22 at 8:39 PM
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Robert Berman Sells 10,000 SharesBiohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Robert Berman Sells 10,000 Shares
www.americanbankingnews.com - December 20 at 8:58 PM
Biohaven Pharmaceutical (BHVN) Downgraded by Zacks Investment Research to HoldBiohaven Pharmaceutical (BHVN) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - December 19 at 4:50 PM
Canaccord Genuity Begins Coverage on Biohaven Pharmaceutical (BHVN)Canaccord Genuity Begins Coverage on Biohaven Pharmaceutical (BHVN)
www.americanbankingnews.com - December 15 at 12:50 PM
Robert Berman Sells 25,000 Shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) StockRobert Berman Sells 25,000 Shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) Stock
www.americanbankingnews.com - December 14 at 8:30 AM
Biohaven Pharmaceutical (BHVN) Given a $48.00 Price Target by Piper Jaffray Companies AnalystsBiohaven Pharmaceutical (BHVN) Given a $48.00 Price Target by Piper Jaffray Companies Analysts
www.americanbankingnews.com - December 11 at 9:46 AM
Biohaven Pharmaceutical Holding Co Ltd (BHVN) VP Sells $109,950.00 in StockBiohaven Pharmaceutical Holding Co Ltd (BHVN) VP Sells $109,950.00 in Stock
www.americanbankingnews.com - December 5 at 7:12 PM
Biohaven Pharmaceutical (BHVN) Lifted to Buy at Zacks Investment ResearchBiohaven Pharmaceutical (BHVN) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - December 4 at 4:34 PM
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Director Gregory Bailey Sells 9,970 SharesBiohaven Pharmaceutical Holding Co Ltd (BHVN) Director Gregory Bailey Sells 9,970 Shares
www.americanbankingnews.com - December 1 at 9:50 PM
Biohaven Pharm (BHVN) Short Interest Down 31.6% in NovemberBiohaven Pharm (BHVN) Short Interest Down 31.6% in November
www.americanbankingnews.com - December 1 at 5:14 AM
Gregory Bailey Sells 600 Shares of Biohaven Pharm (BHVN) StockGregory Bailey Sells 600 Shares of Biohaven Pharm (BHVN) Stock
www.americanbankingnews.com - November 28 at 10:24 PM
Biohaven Pharm (BHVN) Director Sells $533,952.00 in StockBiohaven Pharm (BHVN) Director Sells $533,952.00 in Stock
www.americanbankingnews.com - November 28 at 10:22 PM
Biohaven Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Oral CGRP-Receptor Antagonist RimegepantBiohaven Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Oral CGRP-Receptor Antagonist Rimegepant
www.prnewswire.com - November 27 at 5:12 AM
Biohaven Pharm (BHVN) Downgraded by BidaskClub to "Strong Sell"Biohaven Pharm (BHVN) Downgraded by BidaskClub to "Strong Sell"
www.americanbankingnews.com - November 26 at 8:16 AM
Biohaven Pharm (BHVN) Given Average Recommendation of "Buy" by AnalystsBiohaven Pharm (BHVN) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 24 at 3:56 AM
Biohaven Receives Agreement From FDA on Initial Pediatric Study Plan for Rimegepant, a Second Generation Oral CGRP-Receptor Antagonist for the Acute Treatment of MigraineBiohaven Receives Agreement From FDA on Initial Pediatric Study Plan for Rimegepant, a Second Generation Oral CGRP-Receptor Antagonist for the Acute Treatment of Migraine
finance.yahoo.com - November 20 at 5:47 PM
Featured Company News - Biohaven Pharma Completed Enrollment in First of Two Pivotal Phase-3 Clinical Trials of Rimegepant for Acute Treatment of MigraineFeatured Company News - Biohaven Pharma Completed Enrollment in First of Two Pivotal Phase-3 Clinical Trials of Rimegepant for Acute Treatment of Migraine
finance.yahoo.com - November 20 at 5:46 PM
William Blair Research Analysts Lift Earnings Estimates for Biohaven Pharm (BHVN)William Blair Research Analysts Lift Earnings Estimates for Biohaven Pharm (BHVN)
www.americanbankingnews.com - November 20 at 3:44 AM

SEC Filings

Biohaven Pharmaceutical (NYSE:BHVN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Biohaven Pharmaceutical (NYSE:BHVN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Biohaven Pharmaceutical (NYSE BHVN) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.